Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Zimmer Biomet in a report ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report).

This was the stock's second consecutive day of losses.

Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said adoption of the robot ...

Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.

Zimmer Biomet Holdings, Inc. ZBH is participating in the ongoing American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego, from March 10-14. Here, the company is highlighting ...

Zimmer Biomet CEO Ivan Tornos said he anticipates ASCs to be a major support for growing orthopedic case volumes during the Barclays 27th Annual Global Healthcare Conference. “That is a huge tailwind ...

WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA ...

The Terminator actor teamed up with Zimmer Biomet to raise awareness about osteoarthritis, which affects more than 25 million ...

The stock's fall snapped a four-day winning streak.

Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43.